Medigene AG (FRA:MDG1) ROE % Adjusted to Book Value : -39.26% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Medigene AG ROE % Adjusted to Book Value?

Medigene AG's ROE % for the quarter that ended in Dec. 2023 was -71.85%. Medigene AG's PB Ratio for the quarter that ended in Dec. 2023 was 1.83. Medigene AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -39.26%.

Medigene AG ROE % Adjusted to Book Value Historical Data

The historical data trend for Medigene AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG ROE % Adjusted to Book Value Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-17.98

-26.25

-12.90

-15.08

-30.43

Medigene AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-11.59	56.38	-68.55	-26.94	-39.26

Competitive Comparison of Medigene AG's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Medigene AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medigene AG's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Medigene AG's ROE % Adjusted to Book Value falls into.

Medigene AG ROE % Adjusted to Book Value Calculation

Medigene AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-55.69%	/	1.83
	=	-30.43%

Medigene AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-71.85%	/	1.83
	=	-39.26%

Medigene AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Medigene AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG (FRA:MDG1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (FRA:MDG1) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

MDGEF:USA MDG1:Germany MDG1:Austria

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (FRA:MDG1) Headlines

No Headlines